Literature DB >> 19372547

Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4.

Patrizia Nanni1, Giordano Nicoletti, Arianna Palladini, Annalisa Astolfi, Paola Rinella, Stefania Croci, Lorena Landuzzi, Giada Monduzzi, Valeria Stivani, Agnese Antognoli, Annalisa Murgo, Marianna Ianzano, Carla De Giovanni, Pier-Luigi Lollini.   

Abstract

Rhabdomyosarcoma is a tumor of striated muscle origin that displays defective myogenic differentiation. Terminal myogenesis switches off cell proliferation and migration, hence, the promotion of rhabdomyosarcoma differentiation should antagonize tumor growth and metastasis. Terminal myogenesis is controlled by cell-intrinsic myogenic transcription factors like myogenin and environmental mediators like interleukin 4 (IL-4). We studied whether the expression of myogenin or exposure to IL-4 could promote the myogenesis of poorly differentiating human rhabdomyosarcoma cells RD/12. Forced expression of myogenin amplified myosin expression and the formation of myotube-like elements, inhibited cell migration, and reduced the growth of local tumors and liver metastases in immunodepressed mice. In contrast, exposure to IL-4 promoted cell proliferation and survival, especially at high cell density, inhibited myogenin expression, and myogenesis. Moreover, IL-4 stimulated the directed migration of cells with low myogenin levels, but not of cells with higher (spontaneous or forced) levels. Thus, IL-4, which was known to promote late stages of normal myogenesis, favors growth and migration, and inhibits further differentiation of the myogenic stages attained by rhabdomyosarcoma cells. Strategies to increase myogenin expression and block IL-4 could simultaneously reduce growth and migration, and enhance terminal differentiation of rhabdomyosarcoma, thus contributing to the control of tumor growth and metastatic spread.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19372547     DOI: 10.1158/1535-7163.MCT-08-0678

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  11 in total

Review 1.  Mechanisms of impaired differentiation in rhabdomyosarcoma.

Authors:  Charles Keller; Denis C Guttridge
Journal:  FEBS J       Date:  2013-07-31       Impact factor: 5.542

2.  IL-4R drives dedifferentiation, mitogenesis, and metastasis in rhabdomyosarcoma.

Authors:  Tohru Hosoyama; Mohammed Imran Aslam; Jinu Abraham; Suresh I Prajapati; Koichi Nishijo; Joel E Michalek; Lee Ann Zarzabal; Laura D Nelon; Denis C Guttridge; Brian P Rubin; Charles Keller
Journal:  Clin Cancer Res       Date:  2011-05-01       Impact factor: 12.531

3.  MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomas.

Authors:  E Missiaglia; C J Shepherd; S Patel; K Thway; G Pierron; K Pritchard-Jones; M Renard; R Sciot; P Rao; O Oberlin; O Delattre; J Shipley
Journal:  Br J Cancer       Date:  2010-05-25       Impact factor: 7.640

4.  Overexpression of the skNAC gene in human rhabdomyosarcoma cells enhances their differentiation potential and inhibits tumor cell growth and spreading.

Authors:  Janine Berkholz; Weronika Kuzyniak; Michael Hoepfner; Barbara Munz
Journal:  Clin Exp Metastasis       Date:  2014-09-11       Impact factor: 5.150

5.  Interleukin-4 Receptor Inhibition Targeting Metastasis Independent of Macrophages.

Authors:  Megan M Cleary; Narendra Bharathy; Jinu Abraham; Jin-Ah Kim; Erin R Rudzinski; Joel E Michalek; Charles Keller
Journal:  Mol Cancer Ther       Date:  2021-04-14       Impact factor: 6.261

6.  Rhabdomyosarcomas in aging A/J mice.

Authors:  Roger B Sher; Gregory A Cox; Kevin D Mills; John P Sundberg
Journal:  PLoS One       Date:  2011-08-10       Impact factor: 3.240

Review 7.  Caveolins in rhabdomyosarcoma.

Authors:  Stefania Rossi; Pietro Luigi Poliani; Cristina Missale; Eugenio Monti; Alessandro Fanzani
Journal:  J Cell Mol Med       Date:  2011-12       Impact factor: 5.310

8.  c-Myb regulates tumorigenic potential of embryonal rhabdomyosarcoma cells.

Authors:  Petr Kaspar; Jan Prochazka; Michaela Efenberkova; Attila Juhasz; Vendula Novosadova; Radislav Sedlacek
Journal:  Sci Rep       Date:  2019-04-19       Impact factor: 4.379

9.  LEF1 reduces tumor progression and induces myodifferentiation in a subset of rhabdomyosarcoma.

Authors:  Julia Dräger; Katja Simon-Keller; Tobias Pukrop; Florian Klemm; Jörg Wilting; Carsten Sticht; Kai Dittmann; Matthias Schulz; Ivo Leuschner; Alexander Marx; Heidi Hahn
Journal:  Oncotarget       Date:  2017-01-10

10.  CASZ1 induces skeletal muscle and rhabdomyosarcoma differentiation through a feed-forward loop with MYOD and MYOG.

Authors:  Zhihui Liu; Xiyuan Zhang; Haiyan Lei; Norris Lam; Sakereh Carter; Oliver Yockey; Max Xu; Arnulfo Mendoza; Edjay R Hernandez; Jun S Wei; Javed Khan; Marielle E Yohe; Jack F Shern; Carol J Thiele
Journal:  Nat Commun       Date:  2020-02-14       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.